TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30985709

Group type: COMPARATOR
Intervention: Custom-made LSO with metallic stays (C group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ready-made LSO without metallic stays (R group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No LSO (N group)
Number of subjects: 73
Study: 26701153

Group type: EXPERIMENTAL
Intervention: TV only
Number of subjects: 15600

Group type: EXPERIMENTAL
Intervention: TV plus community activations
Number of subjects: 15600

Group type: COMPARATOR
Intervention: Control (non-randomised)
Number of subjects: 15600
Study: 23522152

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure based on clinical presentation of UTI, pyuria, and procalcitonin (PCT) levels.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) integrated into an interdisciplinary assessment bundle.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group conforming to the guidelines.
Number of subjects: 250
Study: 20496000

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically appropriate interventions to increase hepatitis B knowledge, serologic testing, and vaccination.
Number of subjects: 97
Study: 19453311

Group type: EXPERIMENTAL
Intervention: Orally disintegrating ondansetron
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 16430540

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol + Esmolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metohexital
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metohexital + Esmolol
Number of subjects: 80
Study: 15261895

Group type: EXPERIMENTAL
Intervention: Dietary intervention (Body and Soul program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 11737100

Group type: EXPERIMENTAL
Intervention: SLA implants
Number of subjects: 32
Study: 9086420

Group type: EXPERIMENTAL
Intervention: PGE2 gel and membrane stripping
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Placebo gel and membrane stripping
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PGE2 gel and no membrane stripping
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo gel and no membrane stripping
Number of subjects: 150
Study: 1375082

Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral supplement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 4057126

Group type: EXPERIMENTAL
Intervention: Psychological group treatment aimed at weight reduction, improvement of stress coping, and reduction of salt‐intake, conducted over 16 therapy sessions by trained lay therapists.
Number of subjects: 261

Group type: COMPARATOR
Intervention: Waiting control group (no specific intervention mentioned).
Number of subjects: 261
Study: 31404055

Group type: EXPERIMENTAL
Intervention: activL Artificial Disc
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control TDR (ProDisc-L or Charité)
Number of subjects: 324
Study: 29283931

Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval aerobic training (IA)
Number of subjects: 0
Study: 26359780

Group type: EXPERIMENTAL
Intervention: Gradual training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sudden training group
Number of subjects: 0
Study: 24612497

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) program in intervention nursing homes
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control region (no ACP program)
Number of subjects: 575
Study: 22686512

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline (40 mL, 2.5 mg/mL bupivacaine and 5 μg/mL adrenaline)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Saline solution (40 mL, 0.9%)
Number of subjects: 260
Study: 20491047

Group type: EXPERIMENTAL
Intervention: Topical mydriasis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mydriasert
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intracameral mydriasis
Number of subjects: 90
Study: 17907480

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Multi Protection Toothpaste (5.5% potassium citrate)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sensodyne Total Care F Toothpaste (3.75% potassium chloride)
Number of subjects: 75
Study: 16232082

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.5 mg/kg per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (non-diseased, n=22)
Number of subjects: 18
Study: 12090747

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin dalteparin
Number of subjects: 629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629
Study: 10194091

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 300 mg i.m. every 3 weeks for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone administration for 1 year
Number of subjects: 51
Study: 7761078

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5‐10 mg weekly)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Other therapies (im. gold 50 mg weekly or per os steroid max. 10 mg daily)
Number of subjects: 13
Study: 2183079

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP5)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (young healthy adults)
Number of subjects: 108
Study: 7286051

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 75 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 100 mg
Number of subjects: 134
Study: 31088512

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measuring cerebral oxygen saturation (rSO2)
Number of subjects: 118
Study: 27892891

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg loading dose within 18 hours before surgery, followed by 40 mg maintenance dose starting at least 12 hours after surgery for 7 days)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Placebo (80 mg loading dose within 18 hours before surgery, followed by placebo maintenance dose)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 648
Study: 26483221

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 23554155

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21245790

Group type: COMPARATOR
Intervention: Sham spinal manipulation therapy (12 treatments over 1 month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal manipulation therapy (12 treatments over 1 month, no maintenance)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy with maintenance (12 treatments over 1 month, maintenance every 2 weeks for 9 months)
Number of subjects: 60
Study: 19563364

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 17192450

Group type: EXPERIMENTAL
Intervention: Mandatory abdominal CT imaging
Number of subjects: 152

Group type: COMPARATOR
Intervention: Selective abdominal CT imaging
Number of subjects: 152
Study: 15036568

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 20
Study: 11427783

Group type: EXPERIMENTAL
Intervention: Physical activity (light, moderate, vigorous intensity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training and aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise dose
Number of subjects: 0
Study: 9931794

Group type: EXPERIMENTAL
Intervention: Early extubation (within 6 h postoperatively) after transmediastinal esophagectomy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Prolonged ventilation (> 24 h) after transmediastinal esophagectomy
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Early extubation (within 6 h postoperatively) after transthoracic esophagectomy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Prolonged ventilation (> 24 h) after transthoracic esophagectomy
Number of subjects: 235
Study: 8183099

Group type: EXPERIMENTAL
Intervention: 15N-alanine infusion
Number of subjects: 5
Study: 3369320

Group type: EXPERIMENTAL
Intervention: Follow-up interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30954200

Group type: EXPERIMENTAL
Intervention: Unna's boot (compression therapy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Noncompression therapy (conventional dressing)
Number of subjects: 15
Study: 28822300

Group type: EXPERIMENTAL
Intervention: 1000ml of mineral water within 10min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no water intake)
Number of subjects: 23
Study: 25990361

Group type: EXPERIMENTAL
Intervention: Carbapenems
Number of subjects: 79

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 79
Study: 23299526

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 831
Study: 21067945

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 110
Study: 18201859

Group type: EXPERIMENTAL
Intervention: Narrative information
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Didactic information
Number of subjects: 353
Study: 16836503

Group type: EXPERIMENTAL
Intervention: 1 microg low dose test (LDT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 250 microg standard dose test (SDT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 33
Study: 12617260

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 137
Study: 10823311

Group type: EXPERIMENTAL
Intervention: Vitamin C (3 g/d) and Vitamin E (1500 IU/d) for 8 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8900501

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (TA) 4.2 +/- 0.5 mg/kg orally in a single dose
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (TA)
Number of subjects: 55
Study: 1710489

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABVD combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracycline-based combinations
Number of subjects: 0
Study: 6512981

Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) administered orally at doses of 50 to 100 mg/kg/day for children and 3 g/day for adults for 5 days.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) treatment.
Number of subjects: 47
Study: 30978117

Group type: EXPERIMENTAL
Intervention: HMOX1 rs2071746 polymorphism in PE patients
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Control group (1720 healthy women)
Number of subjects: 1235
Study: 31630278

Group type: EXPERIMENTAL
Intervention: Metabolomic profiling of plasma samples using proton nuclear magnetic resonance spectroscopy (1H NMR)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Two-metabolite model (lactate and acetate)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Second metabolite model (D-glucose, pyruvate, acetoacetate)
Number of subjects: 128
Study: 26683409

Group type: EXPERIMENTAL
Intervention: Microwave disinfection once a week for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microwave disinfection three times a week for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline (control group)
Number of subjects: 40
Study: 26197776

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 5‐HT₃ receptor antagonist with dexamethasone and aprepitant
Number of subjects: 38

Group type: COMPARATOR
Intervention: 5‐HT₃ receptor antagonist with dexamethasone
Number of subjects: 38
Study: 24724983

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol sublingually and 20 IU oxytocin intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: 20 IU of intravenous oxytocin alone
Number of subjects: 120
Study: 22968678

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 350
Study: 19640954

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation with Bifidobacterium lactis and resistant starch
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prebiotic intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Probiotic intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 17466857

Group type: EXPERIMENTAL
Intervention: Pentacam measurements of central corneal thickness (CCT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pentacam measurements of peripheral corneal thickness
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Reliability of consecutive measurements
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Correlation between age and corneal thickness
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Reliability of pachymetry measurements
Number of subjects: 76
Study: 15229756

Group type: EXPERIMENTAL
Intervention: American patients (higher invasive care)
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Canadian patients (more conservative care)
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 1512
Study: 11262775

Group type: EXPERIMENTAL
Intervention: Total joint arthroplasty (TJA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 48
Study: 9731852

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intracervical gel (Prepidil)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study: 7994450

Group type: EXPERIMENTAL
Intervention: Intensified treatment aiming at a blood pressure < or = 80 mmHg diastolic (group A)
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Unchanged therapy (group B)
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: Intensified treatment (group A)
Number of subjects: 2127
Study: 2481558

Group type: EXPERIMENTAL
Intervention: Intracavitary bleomycin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intracavitary talc
Number of subjects: 22
Study: 1161965

Group type: EXPERIMENTAL
Intervention: clomipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: clomipramine and tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: desipramine and clomipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: desipramine and tryptophan
Number of subjects: 0
Study: 31030233

Group type: EXPERIMENTAL
Intervention: Elective course on 3D reconstruction and printing
Number of subjects: 30
Study: 28597103

Group type: EXPERIMENTAL
Intervention: Strength training (STR)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ski-ergometer training (ERG)
Number of subjects: 33
Study: 25012806

Group type: EXPERIMENTAL
Intervention: Transcervical 30 mL Foley balloon (FB)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Transcervical 60 mL Foley balloon (FB)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Transcervical 30 mL or 60 mL Foley balloon (FB)
Number of subjects: 199
Study: 23589387

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 620
Study: 21996929

Group type: EXPERIMENTAL
Intervention: Occupational inhalation exposure to carbon black (CB)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy unexposed male office workers (referent group)
Number of subjects: 72
Study: 18262711

Group type: EXPERIMENTAL
Intervention: Supine position (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Prone position (group B)
Number of subjects: 75
Study: 16840744

Group type: EXPERIMENTAL
Intervention: Infliximab (3 or 5 mg/kg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 15115092

Group type: EXPERIMENTAL
Intervention: HIV exposure category (homosexual/bisexual contact)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CD4 cell counts of 200-500/mm3
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CD4 cell counts above 500/mm3
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall PPD positivity
Number of subjects: 600
Study: 11021769

Group type: EXPERIMENTAL
Intervention: Pivagabine (1800 mg/day for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9167761

Group type: EXPERIMENTAL
Intervention: Etoposide at a dose of 50 mg/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Etoposide at a dose of 50 mg/d with G-CSF
Number of subjects: 29
Study: 8490006

Group type: EXPERIMENTAL
Intervention: Calcium (165 mg Ca as CaCl2) added to a hamburger meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium (165 mg Ca as CaCl2) added to a wheat roll
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control studies to ensure haem-Fe degradation
Number of subjects: 0
Study: 3026552

Group type: EXPERIMENTAL
Intervention: Ovolactovegetarian diet
Number of subjects: 58

Group type: COMPARATOR
Intervention: Typical omnivorous diet
Number of subjects: 58
Study: 31079087

Group type: EXPERIMENTAL
Intervention: Sensor-guided balancing
Number of subjects: 222

Group type: COMPARATOR
Intervention: Manual balancing
Number of subjects: 222
Study: 29696918

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with diane‐35
Number of subjects: 60

Group type: COMPARATOR
Intervention: diane‐35 alone
Number of subjects: 60
Study: 26786573

Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin D3 once weekly for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24874782

Group type: EXPERIMENTAL
Intervention: Intensive community-based group intervention focusing on diet, physical activity, and peer support
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (two 3-hour group sessions of diabetes self-management education)
Number of subjects: 61
Study: 22698027

Group type: EXPERIMENTAL
Intervention: Individualized lifestyle counseling delivered primarily via telephone
Number of subjects: 230

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 230
Study: 19439067

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/kg/min)
Number of subjects: 7
Study: 17879948

Group type: EXPERIMENTAL
Intervention: Intranasal IM862 daily for 6 months or until disease progression.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo daily for 6 months or until disease progression.
Number of subjects: 71
Study: 15994014

Group type: EXPERIMENTAL
Intervention: Normal compression (15 mmHg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low compression (10 mmHg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both compression levels
Number of subjects: 60
Study: 11944005

Group type: EXPERIMENTAL
Intervention: Initial submissions approved for recording (75%)
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Final score after resubmissions
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Initial score of sites approved after 3 or more submissions
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Accuracy for left ventricular internal end-diastolic diameter (LVIDd)
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Accuracy for ejection fraction (EF)
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Reproducibility for LVIDd
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Reproducibility for EF
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Recording scores at baseline, 4, 12, and 18 months
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Power analysis for LVIDd
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Power analysis for EF
Number of subjects: 5010
Study: 9819037

Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant activated factor VII (rFVIIa) targeting a factor VII level of 10 IU/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant activated factor VII (rFVIIa)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Parallel infusion of heparin, saline or dextrose‐saline
Number of subjects: 26
Study: 7860545

Group type: COMPARATOR
Intervention: Thrombotic Stroke (TS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Haemorrhagic Stroke (HS)
Number of subjects: 50
Study: 2521435

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 7 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 13 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.7 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.0 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.3 micrograms/kg
Number of subjects: 80
Study: 1111368

Group type: EXPERIMENTAL
Intervention: Morphine-nitrous oxide anesthesia (2 mg/kg morphine and 70% nitrous oxide in oxygen)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (normal mean arterial blood pressure)
Number of subjects: 5
Study: 31775404

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium (PS) 40 mg administered 30 minutes before incision, 12 hours after THA, and every 12 hours for 2 days postoperatively
Number of subjects: 141

Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 141